NC State Basketball

NC State Checks In At No. 40 In Initial NET Rankings

The NCAA released its initial NET rankings on Monday, and NC State under first-year head coach Will Wade checked in at No. 40 nationally.
December 2, 2025
14k Views
103 Comments
Story Poster
Photo by Steve Murphy/Inside Pack Sports

The NCAA released its initial NET rankings on Monday, and NC State under first-year head coach Will Wade checked in at No. 40 nationally.

NC State (5-2) is currently 0-1 in Quad 1 games and 2-1 in Quad 2 games with a 3-0 mark in Q3/Q4 matchups.  

The remaining non-conference schedule will also give the Pack more opportunities for Quad 1 and Quad 2 wins.  Here is a look at how the rest of the non-conference schedule sets up for the Wolfpack with three more Q1/Q2 games left to play.

Net Opponent Record Location Current Quad Opportunity
30 Auburn 6-2 ROAD Q1
210 UNC Asheville 2-4 HOME Q3
125 Liberty 3-2 HOME Q3
17 Kansas 6-2 HOME Q1
337 Texas Southern 0-5 HOME Q4
96 Ole Miss 5-2 NEUTRAL Q2

Also, the ACC is in a much better spot this season. 

Eight teams are currently ranked inside the Top 50 of the NET: Duke (No. 2), Louisville (No. 6), UNC (No. 26), Virginia (No. 31), Clemson (No. 34), Miami (No. 38), SMU (No. 39) and NC State (No. 40).

Here is a look at how NC State’s ACC schedule lines up based on the initial NET rankings.

Net Opponent Location Current Quad Opportunity
56 Wake Forest HOME Q2
31 Virginia HOME Q2 (1 spot from Q1)
166 Boston College ROAD Q3
82 Florida State ROAD Q2
201 Georgia Tech HOME Q4
34 Clemson ROAD Q1
147 Pittsburgh ROAD Q3
90 Syracuse HOME Q3
56 Wake Forest ROAD Q1
39 SMU ROAD Q1
84 Virginia Tech HOME Q3
9 Louisville ROAD Q1
38 Miami HOME Q2
26 North Carolina HOME Q1
31 Virginia ROAD Q1
86 Notre Dame ROAD Q2
2 Duke HOME Q1
107 Stanford HOME Q3

So in conference there are, as of now, seven Q1 and five Q2 remaining games for the Wolfpack with just one Q4 game (Georgia Tech).

103 Comments
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.